ChromaDex Corporation Stock News

ChromaDex (CDXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

ChromaDex Corporation (NASDAQ:CDXC ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tom Shumaker - Investor Relations Robert Fried - Chief Executive Officer Brianna

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 8.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference ca

ChromaDex Corporation (NASDAQ:CDXC ) Q2 2022 Results Conference Call August 10, 2022 4:30 AM ET Company Participants Heather Van Blarcom - Senior Vice President of Legal and Corporate Secretary Robert

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results f

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ASN--ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CER

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Oppenheimer--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be present

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #LDMicro--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting

ChromaDex Corp (NASDAQ: CDXC) has agreed to establish a joint venture through its wholly-owned subsidiary ChromaDex Asia Limited.  ChromaDex Asia is expected to assume the distribution agreement�

Within the last quarter, ChromaDex (NASDAQ:CDXC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex Corporation (NASDAQ:CDXC ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Rob Fried – Chief Executive Officer Kevin Farr – Chief Financial Officer Brianna

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock